Best Neurology Companies in Washington, United States
The 32 best Neurology companies in Washington, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Achieve Life Sciences.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Washington
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Achieve Life Sciences Developer of plant-based alkaloid for treating smoking cessation 37Funding top 11%News top 42%Moat top 48%Tech top 50% All 7 signals ▾Fundingtop 11% Newstop 42% Moattop 48% Techtop 50% Globalbottom 44% Marketbottom 40% Growthbottom 34% Funding: Raised $264M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) News: 9 BI events in 12 mo (of 54 tracked, 8 types) · -53% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $264M | 6 mo ago | Public | 25 25 → 40 (+60%) | — | WordPress Block EditorWordPressMySQL+17 | — | — |
| 2 | Shape Therapeutics Developer of RNA-targeted therapies intended to treat multiple diseases | $148M | 63 mo ago | Series B | 117 | Prashant Mali Co-Founder | WordPress Block EditorWordPressMySQL+19 | 175 patents AAV vector production optimization and engineered guide RNA design for gene therapy | — |
| 3 | AltPep Developer of diagnostics and therapeutics for amyloid diseases | $120M | 40 mo ago | Series B | 5 | Valerie Daggett Founder & CEO | WordPressApple iCloud MailMySQL+15 | — | — |
| 4 | Athira Pharma Developer of drugs for neurodegenerative diseases | $110M | 71 mo ago | Public | 62 62 → 54 (-13%) | Mark Litton President and CEO | DrupalPHPAmazon Web Services+25 | — | — |
| 5 | Impel NeuroPharma Developer of an intranasal drug delivery technology for CNS diseases | $98M | 67 mo ago | Public | 158 | — | — | 129 patents Precision intranasal drug delivery devices and formulations for targeted nasal administration | — |
| 6 | Cajal Neuroscience Developer of drugs for neurodegenerative disease based on genetic screening, and multi-omics approach | $96M | 47 mo ago | Series A | 60 | Ian Peikon Co-Founder | — | — | — |
| 7 | Cerevast Medical device company developing innovative ultrasound and microsphere therapies | $47M | 140 mo ago | Series C | 5 | Bradford Zakes Chief Executive Officer | — | — | — |
| 8 | Cadence Neuroscience Developer of medical devices for treating neurological disorders | $41M | 44 mo ago | Series B | 17 | Kent Leyde CEO | — | — | — |
| 9 | Allozyne Protein therapeutics for CNS diseases such as multiple sclerosis. | $40M | 158 mo ago | Acqui-Hired | 6 | Dee Datta Ex-Co-Founder | — | 39 patents Engineered eukaryotic cell lines for non‑natural amino acid peptide and nucleic acid production | — |
| 10 | CaaMTech Manufacturer of psychedelic drug discovery & research services | $23M | 62 mo ago | Series A | 8 | Andrew Chadeayne Founder & CEO | WordPressMySQLPHP+17 | 351 patents Synthesis and formulation of novel tryptamine-based psychoactive pharmaceutical compounds | — |
| 11 | Aqueduct Critical Care Novel products to manage Cerebral Spinal Fluid (CSF) pressure | $10M | 100 mo ago | Series A | 13 | — | — | — | — |
| 12 | Proniras Developing novel small-molecule therapeutics for substance use and CNS disorders | $9M | 34 mo ago | Series B | 2 | — | — | 17 patents Pharmaceutical methods for nerve‑agent seizure treatment and opioid withdrawal management | — |
| 13 | Aqueduct Neurosciences Implantable shunt to treat hydrocephalus | $7M | 118 mo ago | Deadpooled | — | Tom Clement CEO | — | 7 patents Intracranial fluid drainage systems with pressure reference assemblies for monitoring | — |
| 14 | Kurve Therapeutics Developer of drug delivery technology to treat neurodegenerative diseases | $3M | 163 mo ago | Seed | 10 | Glenn Cornett Co-Founder | WordPressMySQLPHP+31 | — | — |
| 15 | Precyte Early disease detection and drug development through blood-based assay platform | $2M | 133 mo ago | Funding Raised | 3 | Jennifer Smith Co-Founder & CSO | — | 4 patents In vitro lung cancer cellular response assays for drug screening and therapeutic evaluation. | — |
| 16 | Pacific Northwest Biotechnology Mid-stage biopharmaceutical company focusing on angiotensin-related peptides and peptidomimetics for… | $800K | 191 mo ago | Early Stage | — | Joseph Harding Co-Founder & CEO | — | — | — |
| 17 | NaviSonics A micro-ultrasound surgical navigation system for neurological procedures | $500K | 122 mo ago | Seed | — | Samuel R. Browd Co-Founder & CMO | — | 7 patents Image-guided navigation systems for precise positioning of medical devices | — |
| 18 | Quadralynx Developer of vocal biomarker technology for neurological disease management | $256K | 58 mo ago | Funding Raised | — | Gavin Rowe Co-Founder & CEO | — | 5 patents Wearable acoustic sensors for health monitoring and speech/veterinary therapy. | — |
Top 12 Neurology companies in Washington
#1
Public · Seattle, Washington · founded 1991 · 25 employees$263.6Mraised▾
Developer of plant-based alkaloid for treating smoking cessation. The company is developing Cytisinicline, which is a plant-based alkaloid with a binding affinity to the α4β2 nicotine receptor. The candidate is expected to block nicotine cravings and reduce the severity of nicotine withdrawal symptoms.
- Apr 2026Post IPO$180M
- Feb 2024Post IPO$60M
- Nov 2022Post IPO$18.9M
- Aug 2021Grant (prize money)$2.8M
#2
Series B · Seattle, Washington · founded 2014 · 5 employees$120.4Mraised▾
Developer of diagnostics and therapeutics for amyloid diseases. The company SOBA diagnostics and SOBIN therapeutics targeting the toxic soluble oligomers for the early detection and treatment of amyloid diseases such as Alzheimer's and Parkinson's.
- Jun 2023Series B$52.9M
- Jul 2022Series B$44.4M
- Jan 2021Series A$23.1M
#3
Series A · Seattle, Washington · founded 2020 · 60 employees$96Mraised▾
Developer of drugs for neurodegenerative disease based on genetic screening, and multi-omics approach. The company develops viral tools and platform to screen for the targets with functional impact on neurodegenerative disease progression. It also offers functional genetic screening, and multi-omics approaches to develop precision medicine for neurodegenerative disease.
- Nov 2022Series A$96M
#4
Series B · Seattle, Washington · founded 2018 · 117 employees$147.5Mraised▾
Developer of RNA-targeted therapies intended to treat multiple diseases. It provides platforms that includes a proprietary suppressor technology that permits premature stop codon readthrough, a precision RNA editing technology that uses endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform that generate tissue-tropic AAVs.
- Jul 2021Series B$112M
- Nov 2019Series A$35.5M
#5
Public · Seattle, Washington · founded 2011 · 62 employees$109.8Mraised▾
Developer of drugs for neurodegenerative diseases. The company's product is Fosgonimeton for the treatment of Alzheimer’s, Parkinson’s, various dementias, and others. Also, have two drug candidates ATH-1020 for neuropsychiatric indications and ATH-1019 for peripheral indications.
- Dec 2020Grant (prize money)$15M
- Sep 2020Grant (prize money)$15.2M
- Jun 2020Series B$89M
- Jan 2020Series B$3.8M
#6
Public · Seattle, Washington · founded 2008 · 158 employees$98.4Mraised▾
Developer of an intranasal drug delivery technology for CNS diseases. It develops non-invasive Precision Olfactory Delivery (POD) nasal devices to develop therapies for Alzheimer's, migraine, and other diseases of the central nervous system. The technology allows a variety of drugs including biologics to be delivered to the brain.
- Mar 2021Conventional Debt$7.5M
- Dec 2018Series D$67.5M
- Dec 2016Series C$21M
- Nov 2016Series C$22.3M
#7
Series B · Redmond, Washington · founded 2016 · 17 employees$41Mraised▾
Cadence Neuroscience is developing medical device therapies for the treatment of neurological disorders such as epilepsy, central pain, and others. The company is developing an implantable device to treat epilepsy.
- Feb 2023Series B$26M
- Oct 2019Series A$15M
- Oct 2019Grant (prize money)—
#8
Series B · Seattle, Washington · founded 2018 · 2 employees$8.9Mraised▾
Developing novel small-molecule therapeutics for substance use and CNS disorders. It is a clinical-stage biotechnology company focused on creating innovative treatments for substance use disorders and specialty central nervous system conditions. Their lead program, tezampanel, is a novel modulator of glutaminergic signaling designed to aid patients recovering from opioid addiction and related conditions. Tezampanel works by reducing brain over-activation in circuits involved in drug withdrawal, addiction, and mental illness without directly targeting the opioid system. This approach has the potential to significantly improve the treatment of opiate withdrawal syndrome, opioid overdoses, and facilitate the transition to long-term medications, ultimately helping patients achieve full remission from their illness. This is a B2B model.
#9
Series C · Bothell, Washington · founded 2009 · 5 employees$46.9Mraised▾
Medical device company developing innovative ultrasound and microsphere therapies, focused on creating first-in-class therapeutic solutions. The company is dedicated to restoring health and improving the quality of life for patients suffering from major diseases. They leverage core expertise in ultrasound and microsphere technologies to develop novel treatments for conditions with limited options. Their clinical-stage programs target ischemic stroke and retinal vein occlusion, addressing significant unmet medical needs. They are committed to developing new treatments to address unmet medical needs, adhering to core values that drive innovation and patient well-being. Their work has a direct social impact by providing solutions for devastating diseases.
- Mar 2015Series C$11.4M
- Dec 2014Series C$10M
- Mar 2014Series B$1.8M
- Apr 2013Series B$14.1M
#10
Series A · Issaquah, Washington · founded 2018 · 8 employees$23.4Mraised▾
Manufacturer of psychedelic drug discovery & research services. They also offers psychedelic formulations, drug safety, efficacy screening, intellectual property to fund progress, and technological innovation services.
- Sep 2021Series A$22M
- 2020Seed$1.4M
#11
Acqui-Hired · Seattle, Washington · founded 2005 · 6 employees$40.5Mraised▾
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. Provides their technology platforms to enable the incorporation of amino acid analogues at any position to create biologics that elicit improved efficacy, tolerability and pharmacology. Its technology also enables the development of next generation antibody-drug conjugates (ADCs). In 2014, Allozyne was acquired by MedImmune.
- Aug 2013Series B$2.5M
- Apr 2013Conventional Debt$900K
- Jun 2012Series B$2M
- Feb 2012Series B$2.5M
#12
Series A · Bothell, Washington · founded 2013 · 13 employees$10.3Mraised▾
Aqueduct Critical Care is developing novel products to manage Cerebral Spinal Fluid (CSF) pressure and flow for patients in Critical Care following brain surgery. It addresses the critical care problem of managing inter-cranial pressure. Claims that it's working prototypes demonstrate the ability to allow the patient to move and minimize attention from nursing staff.
- Jun 2018Series A$821.6K
- Dec 2017Series A—
- Sep 2017Series A$640K
- Jan 2017Series A$2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neurotech in Washington is moving
A read on the academic research around Neurotech in Washington — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 228 papers.
- University of Washington130
- Washington University in St. Louis80
- George Washington University16
- University of Washington Medical Center7
- University of Washington Applied Physics Laboratory4
- Deep brain stimulation5→18
- Interface (matter)1→7
- Brain–computer interface3→6
- Optogenetics1→4
- Brain stimulation2→5
- Epilepsy1→11
- Neuroscience9→15
- Brain stimulation1→7
- Neurostimulation2→7
- Physical medicine and rehabilitation2→6
- Neuromodulation2→4
- Neuroscience3→4
- Brain stimulation2→3
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.